#United States #Delray Beach #Therapeutics #Plasma Fractionation #Immunoglobulins

Plasma Fractionation Market Forecast

The global plasma fractionation market is poised for substantial growth, with projections indicating an increase from USD 36.44 billion in 2026 to USD 52.58 billion by 2031. This expansion represents a compound annual growth rate (CAGR) of 7.6% throughout the forecast period. According to a report from MarketsandMarkets, several factors are contributing to this growth, including rising clinical demand for plasma-derived therapies across multiple medical specialties such as immunology, neurology, hematology, critical care, and pulmonology.

Market Dynamics

Demand Drivers

The surge in demand for plasma products is driven by their crucial applications in managing various conditions, including immunodeficiencies, autoimmune disorders, neurological diseases, and critical-care scenarios. Immunoglobulins, which accounted for 51.1% of the plasma fractionation market share in 2025, are particularly in demand due to their critical therapeutic roles. As healthcare providers increasingly turn to plasma-derived therapies, the pressure on plasma collection organizations and manufacturers to enhance their operational capacities intensifies.

Regional Analysis

In 2025, North America dominated the plasma fractionation market with a significant 45.5% share, primarily due to its robust healthcare infrastructure, established plasma collection networks, and high utilization rates of plasma-derived therapies. Key players in this region are actively investing in expanding their fractionation and purification technologies to maintain their competitive edge.

Market Segmentation

By Product Type

The plasma fractionation market is segmented into several categories:

• - Immunoglobulins (the fastest-growing segment)
• - Coagulation factor concentrates
• - Albumin
• - Protease inhibitors
• - Other plasma products

Among these, immunoglobulins are set to experience the highest growth rate, propelled by their necessity in treating a wide array of medical conditions. As cases of primary immunodeficiencies and autoimmune diseases rise, the need for immunoglobulin therapies is expected to compound, thereby supporting substantial investments in immunoglobulin production.

By Application

Applications of plasma-derived products are primarily classified into:

• - Therapeutics
• - Academic preclinical research

The therapeutics segment, accounting for 95.0% of the market, is likely to witness the highest growth, as healthcare utilization continues to rise. The increasing prevalence of conditions requiring plasma-derived therapies, combined with investments in plasma collection infrastructure, promises to support this segment's expansion.

Investment Trends

The plasma fractionation landscape is characterized by rising investment activities, focusing on enhancing plasma collection capabilities and expanding manufacturing facilities. For example, CSL's recent announcement of a USD 1.5 billion investment to bolster its production of plasma-derived therapies underscores the industry's strategic direction. Similarly, Takeda's USD 230 million investment to increase its facility’s capacity is a testament to the critical importance of operational scalability in the market.

Competitive Landscape

The competitive environment remains highly consolidated, with major players such as CSL, Grifols, Takeda, and Octapharma collectively holding a substantial share of the market. These companies are not only advancing their production capabilities but are also optimizing their plasma utilization to enhance efficiency. Mergers and acquisitions are prevalent as companies seek to strengthen their plasma collection networks and broaden their portfolios of plasma-derived products. Recent acquisitions, such as Kedrion's purchase of Plasmafera, illustrate the industry's movement towards creating more comprehensive product ecosystems to meet demand.

Conclusion

The plasma fractionation market is on an upward trajectory, driven by increasing clinical demand and ongoing strategic investments. As innovations in plasma collection and fractionation technologies continue to emerge, the importance of these therapies in modern medicine will only grow, shaping the future of healthcare.

Key Market Players

Leading companies in the plasma fractionation market include:

• - CSL
• - Takeda Pharmaceutical Company Limited
• - Grifols, S.A.
• - Octapharma AG
• - Kedrion S.p.A.

These entities play pivotal roles in shaping market dynamics through their commitment to expanding production capabilities and improving therapy availability to meet the growing global demand for plasma-derived treatments.